Beyond the Headlines: What We Really Know About Autism

Pregnancy is often described as a magical time. Expecting parents brainstorm baby names, decorate nurseries, and read every parenting book in sight. Everyone wants to be a good parent—after all, it is one of the most important and difficult jobs there is.

With autism now estimated at 1 in 31 children—and even higher for boys—many mothers-to-be feel pressure to avoid anything that might raise the risk. They skip dental work, delay coloring their hair, give up tuna sandwiches, and of course, abstain from smoking and drinking. So when headlines warn that acetaminophen use during pregnancy “causes” autism, the fear can feel overwhelming.

But this claim grossly oversimplifies one of the most complex neurological conditions. Yes, some studies suggest a correlation between acetaminophen use in pregnancy and autism. But why was the acetaminophen used in the first place? Fever during pregnancy is already known to increase risks for complications and birth defects. In other words, the underlying condition—not the medication—may be the true culprit. When Harvard and Mount Sinai researchers reviewed the evidence, they found the studies too inconsistent to combine in a meaningful meta-analysis. And the most comprehensive study to date, conducted in Sweden, found no causal link at all.

The truth is, autism is far too complex to be reduced to a single explanation. Genetics play a central role, and changes in diagnostic criteria have also driven rising prevalence rates. Since 2013, a diagnosis no longer requires a language delay; deficits in social communication alone can qualify. Asperger’s is no longer a separate category—everyone now receives the same autism label, defined by levels of severity from 1 to 3.

If pregnancy fears sometimes oversimplify causes, treatment hopes can oversimplify solutions. Take leucovorin, also known as folinic acid. In oncology, it has a proven role as a “rescue drug,” protecting healthy cells from chemothetapy’s toxic effects by bypassing blocked folate pathways. Some researchers have hypothesized that it could also “rescue” folate metabolism in the brain, especially for children with autism who carry antibodies that block folate transport across the blood–brain barrier. A handful of small studies have suggested promising results in communication and behavior.

But once again, plausibility is not proof. Large, rigorous clinical trials are still lacking. Which brings us to the same recommendation as with any experimental biological treatment: consult your clinical team, and above all, collect robust baseline data before trying the medication. Parents need measurable indicators—whether in language, social interaction, or daily functioning—to know if real improvement is happening, or if hopeful perception is leading the way.

The bottom line: both causes and treatments for autism are complicated. Mothers should not be made to feel guilty over unproven risks, and parents of children with autism should not be pressured into chasing every experimental therapy without evidence. Parenting is hard enough. Families deserve clarity, honesty, and support—not blame and false promises.

 

Mariela Vargas-Irwin, PSYD, BCBA-D, LABA obtained her doctoral degree from Rutgers University, completed her internship at Boston Children’s Hospital and did post-doctoral training at Baker Children’s Center and has over 30 years of experience working with children with autism and other developmental disorders. For over 22 years, Vargas-Irwin has been a part of Applied Behavioral Learning Services team in Wellesley and is currently the Executive Director of the organization. www.ablspartners.org